[Vismodegib for basal cell carcinoma: targeted therapy in case of locally advanced or metastasised disease]

The development of the hedgehog pathway inhibitor vismodegib provides a new treatment option for metastasised and locally advanced basal cell carcinoma in which surgical excision or radiotherapy is contraindicated. Only a fraction of patients with basal cell carcinoma are eligible for this therapy, but it is effective in the majority of those who do receive vismodegib. However, development of tumour resistance is quite common and adverse events frequently lead to discontinuation of therapy. Intermittent treatment or combination therapy could reduce the occurrence of tumour resistance and diminish toxicity. We present three patients who were successfully treated with vismodegib: a 73-year-old man with locally advanced basal cell carcinoma, an 82-year-old man with basal cell carcinoma that had metastasised to the lungs, and a 42-year-old man with Gorlin syndrome.

Ultrastructural analysis of reorganization of the periodontium in simulated torsion abnormality and its correction with succinic acid

Morphological study confirmed the positive effect of succinic acid on tissue ultrastructure, energy metabolism in cells of fibroblastic differon, reorganization and neogenesis of intercellular substance of the periodontal connective tissue during the retention period after correction of simulated dental torsion abnormality in dogs.